MX2016011114A - Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. - Google Patents
Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.Info
- Publication number
- MX2016011114A MX2016011114A MX2016011114A MX2016011114A MX2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- methods
- compositions
- treatment
- expressing tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 101150029707 ERBB2 gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011114A true MX2016011114A (es) | 2017-02-20 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011114A MX2016011114A (es) | 2014-02-25 | 2015-02-25 | Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3110942A4 (enExample) |
| JP (1) | JP2017507943A (enExample) |
| KR (2) | KR20160122829A (enExample) |
| CN (1) | CN106661538A (enExample) |
| AU (1) | AU2015223136A1 (enExample) |
| BR (1) | BR112016019534A2 (enExample) |
| CA (1) | CA2940646A1 (enExample) |
| IL (1) | IL247436A0 (enExample) |
| MX (1) | MX2016011114A (enExample) |
| RU (1) | RU2016137834A (enExample) |
| SG (1) | SG11201607036XA (enExample) |
| WO (1) | WO2015130810A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| AU2013232291B8 (en) | 2012-03-12 | 2016-07-21 | Advaxis, Inc. | Suppressor cell function inhibition following listeria vaccine treatment |
| EP3107566A4 (en) | 2014-02-18 | 2017-10-11 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| BR112016020364A2 (pt) * | 2014-03-05 | 2018-01-16 | Advaxis, Inc. | métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo |
| CA2946716A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| SG11201804957VA (en) | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| SG11201901979SA (en) | 2016-11-30 | 2019-04-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en not_active Ceased
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015130810A3 (en) | 2016-01-28 |
| BR112016019534A2 (pt) | 2017-10-24 |
| JP2017507943A (ja) | 2017-03-23 |
| EP3110942A4 (en) | 2017-08-30 |
| EP3110942A2 (en) | 2017-01-04 |
| AU2015223136A1 (en) | 2016-09-22 |
| IL247436A0 (en) | 2016-11-30 |
| NZ723750A (en) | 2024-02-23 |
| KR20240038103A (ko) | 2024-03-22 |
| CA2940646A1 (en) | 2015-09-03 |
| CN106661538A (zh) | 2017-05-10 |
| KR20160122829A (ko) | 2016-10-24 |
| RU2016137834A (ru) | 2018-03-29 |
| SG11201607036XA (en) | 2016-09-29 |
| WO2015130810A2 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011114A (es) | Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. | |
| IL265755A (en) | A chimeric antibody receptor for cancer therapy | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| IL260935A (en) | Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody | |
| IL265786A (en) | Materials and methods for increasing radiotherapy against cancer | |
| TN2016000559A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| IL256543B (en) | A method for treating neuroendocrine tumors that overexpress somatostatin receptors | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| HUE065528T2 (hu) | Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| WO2016070051A3 (en) | Combination therapy for treatment of disease | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| HK1248758A1 (zh) | 包含肽小基因表达系统的基於李斯特菌的组合物及其使用方法 | |
| MA39909A (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
| LT4339615T (lt) | Antikūnai prieš pd-1, skirti naudoti vėžio gydymui | |
| ZA202204223B (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| IL270329B2 (en) | Immunotherapeutic method for tumor treatment | |
| IL290130A (en) | Treatment of insidious tumors in the immune system | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين |